Compare Utilities Select Sector SPDR Fund (XLU) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Utilities Select Sector SPDR Fund vs Zimmer Biomet Holdings Inc — how do they compare? Utilities Select Sector SPDR Fund trades at $43.78, while Zimmer Biomet Holdings Inc trades at $95.26 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while Utilities Select Sector SPDR Fund pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| XLU | ZBH | |
|---|---|---|
52-Week High | $47.73 | $107.71 |
52-Week Low | $41.31 | $79.58 |
Market Cap | — | $18.55B |
Sector | — | Health |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XLU trades at $43.74, up 1.39% with bearish technical signals from moving averages and oscillators. The ETF shows strong institutional call option activity, with 43,489 contracts traded on August 11, 2026, representing an 18% increase over typical volume. Recent news highlights XLU's positioning as an AI power demand play, with utilities gaining attention for data center electricity needs. The fund offers defensive income characteristics with dividend distributions scheduled for June 2026.
XLU faces technical headwinds but benefits from structural AI power demand growth. The ETF's defensive utility holdings provide income stability while capturing electricity infrastructure expansion. Key risks include interest rate sensitivity and regulatory changes, but institutional interest in call options suggests bullish positioning on the AI power theme.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
